Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 10, 2010, Pages 1692-1701

  Nakazato, Kyoumi ^a   Takada, Hisashi ^a   Iha, Masahiko ^b   Nagamine, Takeaki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b South Product Co Ltd   (Japan)

Author keywords

chemokine ligand 12 (CXCL12); fucoidan; liver fibrosis; N nitrosodiethylamine (DEN); transforming growth factor beta 1 (TGF 1)

Indexed keywords

CHEMOKINE; DIETHYLNITROSAMINE; FUCOIDIN; HYDROXYPROLINE; MALONALDEHYDE; MESSENGER RNA; METALLOTHIONEIN; TRANSFORMING GROWTH FACTOR BETA1; MONOCYTE CHEMOTACTIC PROTEIN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLADOSIPHON OKAMURANUS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; FIBROGENESIS; LIPID PEROXIDATION; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEAWEED; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; LIVER LEVEL; TREATMENT OUTCOME;

EID: 77957604111     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06187.x     Document Type: Article

References (49)

1. Friedman SL. Liver fibrosis: from bench to bedside. J. Hepatol. 2003 38 (Suppl 1 S38 S53.
2. Iredale JP. Cirrhosis: new research provided a basis for rational and targeted treatment. BMJ 2003 327 : 143 147.
3. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004 350 : 1646 1654.
4. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005 115 : 209 218.
5. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 2006 10 : 76 99.
6. Kurihara S, Yokoyama F, Inoue H et al. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-β1 in hepatofibrogenesis of rat cirrhosis model. Int. J. Mol. Med. 2007 19 : 313 324.
7. Preaux AM, Mallat A, Resenbaum J, Zafrani ES, Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997 26 : 315 322.
8. Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 1999 5 : 226 230. (Pubitemid 29068532)
9. Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000 119 : 466 478.
10. Cho JJ, Hocher B, Herbst H et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000 118 : 1169 1178.
11. Galli A, Crabb DW, Ceni E et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002 122 : 1924 1940.
12. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effect of D-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997 113 : 1069 1073.
13. Shimizu I, Ma YR, Mizobuchi Y et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999 29 : 149 160.
14. Vendemiale G, Grattagliano I, Caruso ML et al. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in rats: effect of N-acetylcysteine and interferon-α. Toxicol. Appl. Pharmacol. 2001 175 : 130 139.
15. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000 32 : 247 255.
16. Bruck R, Genina O, Aeed H et al. Halofuginone to prevent and treat thioacetamide- induced liver fibrosis in rats. Hepatology 2001 33 : 379 386.
17. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. USA 1999 96 : 12719 12724.
18. Kondou H, Mushiaki S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-beta 1 activation prevents hepatic fibrosis in vivo. J. Hepatol. 2003 39 : 742 748.
19. De Gouville AC, Boullay V, Krysa G et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br. J. Pharmacol. 2005 145 : 166 177.
20. Chizhov AO, Dell A, Morris HR et al. A study of fucoidan from the brown seaweed Chorda filum. Carbohydr. Res. 1999 320 : 108 119.
21. Ruperez P, Ahrazem O, Leal JA. Potential antioxidant capacity of sulfated polysaccharides from the edible marine brown seaweed Fucus vesiculosus. J. Agric. Food. Chem. 2002 50 : 840 845.
22. Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class. Glycobiology 2003 13 : R20 40.
23. Zhao X, Xue C, Li Z, Cai Y, Liu H, Qi H. Antioxidant and hepatoprotective activities of low molecular weight sulfated polysaccharide from Laminaria japonica. J. Appl. Phycol. 2004 16 : 111 115.
24. Veena CK, Josephine A, Preetha AP, Rajesh NG, Varalakshmi P. Mitochondrial dysfunction in an animal model of hyperoxaluria: a prophylactic approach with fucoidan. Eur. J. Pharmacol. 2008 579 : 330 336.
25. Boisson-Vidal C, Zemani F, Caligiuri G et al. Neoangiogenesis induced by progenitor endothelial cells: effect of fucoidan from marine algae. Cardiovasc. Hematol. Agents Med. Chem. 2007 5 : 67 77.
26. Kang KS, Kim ID, Kwon RH, Lee JY, Kang JS, Ha BJ. The Effects of Fucoidan Extracts on CCl4-Induced Liver Injury. Arch. Pharm. Res. 2008 31 : 622 627.
27. Wang J, Zhang Q, Zhang Z, Li Z. Antioxidant activity of sulfated polysaccharide fractions extracted from Laminaria japonica. Int. J. Biol. Macromol. 2008 42 : 127 132.
28. Hayashi S, Itoh A, Isoda K, Kondoh M, Kawase M, Yagi K. Fucoidan partly prevents CCL4-induced liver fibrosis. Eur. J. Parmacol. 2008 580 : 380 384.
29. Cumashi A, Ushakova NA, Preobrazhenskaya ME et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007 12 : 1 42.
30. Chabut D, Fischer AM, Colliec-Jouault S et al. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfated-dependent alpha6 over expression. Mol. Pharmacol. 2003 64 : 696 702.
31. Luyt CE, Meddahi-Pelle A, Ho-Tin-Noe B et al. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J. Pharmacol. Exp. Ther. 2003 305 : 24 30.
32. Zemani F, Benisvy D, Galy-Fauroux I et al. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem. Pharnacol. 2005 70 : 1167 1175.
33. Matsubara K, Xue C, Zhao X, Mori M, Sugawara T, Hirata T. Effects of middle molecular weight fucoidans on in vitro and in vivo angiogenesis of endothelial cells. Int. J. Mol. Med. 2005 15 : 695 699.
34. Soeda S, Kozako T, Iwata K, Shimeno H. Over sulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formations by human umbilical vein endothelial cells: its possible mechanism of action. Biochem. Biophys. Acta 2000 1497 : 127 134.
35. Nagamine T, Takada H, Kusakabe K et al. Intracellular changes of metal elements by fucoidan extracted from Brawn Seaweed. Biol. Trace Elem. Res. 2008 124 : 60 9.
36. Nakazato K, Nakajima K, Kusakabe T, Suzuki K, Nagamine T. Immunohistochemical staining with newly developed metallothionein fragment antibodies against NH2-terminal, middle-regional and COOH-terminal peptides in rabbits. Pathol. Int. 2008 58 : 765 770.
37. Nagaoka M, Shibata H, Kimura-Takagi I et al. Structural study of fucoidan from Cladosiphon okamuranus Tokida. Glycoconj. J. 1999 16 : 19 26.
38. Ellis AJ, Curry VA, Powell EK, Cawston TE. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem. Biophys. Res. Commun. 1994 201 : 94 101.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976 72 : 48 54.
40. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979 95 : 351 358.
41. Bissel DM, Roulot D, George J. Transforming growth factor beta and liver. Hepatology 2001 34 : 859 867.
42. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J. Cell. Physiol. 1994 159 : 51 9.
43. O'Leary R, Rerek M, Wood EJ. Fucoidan modulates the effect of transforming growth factor (TGF)-beta1 on fibroblast proliferation and wound repopulation in vitro models of dermal wound repair. Biol. Pharm. Bull. 2004 27 : 266 270.
44. Murdoch C, Finn A. Chemokine receptors and their role in infectious diseases. Blood 2000 95 : 3023 3043.
45. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Viahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J. Immunol. 2002 169 : 5546 5554.
46. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis. Chest 2007 132 : 1311 1321.
47. Wald O, Pappo O, Safadi R et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur. J. Immunol. 2004 34 : 1164 1174.
48. Mavier P, Martin N, Couchie D, Preaux AM, Laperche Y, Zafraui ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am. J. Pathol. 2004 165 : 1969 1977.
49. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001 61 : 2035 2063.